- Home
- JAZZ vs XPEV Comparison
JAZZ vs XPEV Comparison
Compare JAZZ & XPEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | XPEV |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | Ireland | China |
| Employees | N/A | 19884 |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0B | 14.4B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | JAZZ | XPEV |
|---|---|---|
| Price | $236.27 | $14.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $217.57 | $23.08 |
| AVG Volume (30 Days) | 810.7K | ★ 6.4M |
| Earning Date | 05-05-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.43 | N/A |
| Revenue | ★ $1,618,693,000.00 | N/A |
| Revenue This Year | $6.22 | $25.76 |
| Revenue Next Year | $7.68 | $25.98 |
| P/E Ratio | $53.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $105.00 | $13.98 |
| 52 Week High | $243.32 | $28.20 |
Technical Indicators
Market Signals| Indicator | JAZZ | XPEV |
|---|---|---|
| Relative Strength Index (RSI) | 58.56 | 35.60 |
| Support Level | $224.23 | N/A |
| Resistance Level | $243.32 | $18.35 |
| Average True Range (ATR) | 6.98 | 0.55 |
| MACD | -1.65 | -0.17 |
| Stochastic Oscillator | 60.69 | 13.53 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About XPEV XPeng Inc.
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold about 430,000 EVs in 2025, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.